Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 11:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,055 matching trials from the live ClinicalTrials.gov search.
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, topotecan hydrochloride, WBRT
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
23
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 19 more
Conditions
HIV Infections, Depression
Interventions
Telephone-administered coping improvement therapy, Telephone-administered supportive-expressive therapy, Individual therapy
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
50 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Athens, Ohio
Conditions
Breast Neoplasms
Interventions
Zometa, Epirubicin, Docetaxel, Trastuzumab, External beam radiation, Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Breast Cancer, Lung Cancer, Pulmonary Cancer, Non-Small-Cell Lung Carcinoma, Prostate Cancer, Prostatic Cancer, Gastric Cancer, Stomach Cancer
Interventions
MGCD0103 & Docetaxel
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Conditions
Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
Interventions
enzastaurin, temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combined Pharmaco/Behavior Therapy in Adolescent Smokers

NCT00330187
Conditions
Nicotine Dependence, Nicotine Use Disorder
Interventions
Bupropion SR, Contingency Management, Placebo
Drug · Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Completed Not applicable Interventional Accepts healthy volunteers

Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations

NCT01156610
Conditions
Smoking, Smoking Cessation
Interventions
Tobacco Treatment
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Stomach Cancer, Gastric Cancer
Interventions
5-Fluorouracil, Folinic Acid, Oxaliplatin, Radiotherapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Insomnia Disorder
Interventions
CBT-I in person, CBT-I via Telemedicine, No intervention
Behavioral · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Arthritis
Interventions
Live Music Therapy, Recorded Music Therapy, Control
Other
Lead sponsor
April Armstrong
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Nivolumab, Pembrolizumab
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2037
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Multiple Sclerosis
Interventions
Nurse-Led Purpose-Building Intervention
Behavioral
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Denton, Texas
Completed Phase 2 Interventional Results available

Pembro/Carbo/Taxol in Endometrial Cancer

NCT02549209
Conditions
Endometrial Cancer, Endometrial Adenocarcinoma
Interventions
Pembrolizumab, Paclitaxel, Carboplatin
Drug
Lead sponsor
Daniela Matei, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Mesa, Arizona • Chicago, Illinois • Lake Forest, Illinois + 3 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Improving Quitline Support Study

NCT03538938
Conditions
Tobacco Use Cessation
Interventions
1-Call Quitline Counseling, 4-Call Quitline Counseling, Nicotine patch, Nicotine Patch and Nicotine Lozenge, SmokefreeTXT, No SmokefreeTXT, Financial Incentives for Treatment Engagement, No Financial Incentives for Treatment Engagement
Behavioral · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Advanced Solid Tumors
Interventions
DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
28
States / cities
Tucson, Arizona • Los Angeles, California • Santa Monica, California + 21 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

NCT00001832
Conditions
Melanoma, Neoplasm Metastasis
Interventions
gp100:209-217 (210M), Montanide ISA-51, IL-2, MART-1:26-35(27L), Abl cells, Fludarabine, Cyclophosphamide, GCSF (Growth colony stimulating factor), Apheresis
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Orofacial Myofunctional Disorders, Myo Munchee, Oral Motor Therapy, Maxillary Deficiency
Interventions
Chewing device only, Myo Munchee and Oral Motor Therapy Treatment, Oral Motor Therapy Treatment Arm
Device · Other
Lead sponsor
Myo Munchee (Operations) Pty Ltd
Industry
Eligibility
3 Years to 5 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Conditions
Solid Tumor, Adult
Interventions
research blood draws
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL
Interventions
Rituximab, Copanlisib, Bone Marrow Aspiration/Biopsy, CT Scans, 18F-FDG-PET/CT Scan15, Electrocardigram
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Breast Cancer, Gastric Cancer
Interventions
margetuximab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Bethesda, Maryland • Nashville, Tennessee
Conditions
Distal Femur Fracture
Interventions
Timed Up and Go Test on subjects with ORIF of distal femur fractures, Koos Jr assesment on subjects with ORIF of distal femur fractures, Timed Up and Go Test on subjects with DFR of distal femur fracture, Koos Jr assesment on subjects with DFR of distal femur fracture
Other
Lead sponsor
University of Florida
Other
Eligibility
55 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Active, not recruiting Phase 2 Interventional

177LuPSMA in Renal Cell Carcinoma

NCT06964958
Conditions
Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer
Interventions
177Lu-PSMA-617
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Colonic Neoplasms, Colorectal Neoplasms
Interventions
GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Adjuvant chemotherapy
Drug
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Detroit, Michigan • New York, New York • Cincinnati, Ohio
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Neoadjuvant Chemotherapy (NAC), Immunotherapy (pembrolizumab), Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas